Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block

References

• Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology3, 418–420 (1942).
   Google Scholar
• Gray TC. D-tubocurarine chloride. Proc. R Soc. Med.41, 559–568 (1948).
   PubMedGoogle Scholar
• Foldes FF. The impact of neuromuscular blocking agents on the development of anesthesia and surgery. In: Muscle Relaxants (Second Edition). Agoston S, Bowman WC (Ed.), Elsevier, Amsterdam–New York–Oxford 1–17 (1990).
   Google Scholar
• Durant NN, Katz RL. Suxamethonium. Br. J. Anesth.54, 195–208 (1982).
   PubMed Web of Science ®Google Scholar
• Bowman WC. Neuromuscular block. Br. J. Pharmacol.147(Suppl. 1), S277–S286 (2006).
   PubMed Web of Science ®Google Scholar
• McCourt KC, Salmela L, Mirakhur RK et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anesthesia. Anesthesia53, 867–871 (1998).
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology98, 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• Claudius C, Karacan H, Viby-Mogensen J. Prolonged residual paralysis after a single intubating dose of rocuronium. Br. J. Anesth.99, 514–517 (2007).
   PubMed Web of Science ®Google Scholar
• Eikermann M, Zaremba1 S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br. J. Anes.101, 344–349 (2008).
   PubMed Web of Science ®Google Scholar
• Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. Anesthesiology57, 261–266 (1982).
   PubMed Web of Science ®Google Scholar
• Magorian TT, Lynam DP, Caldwell JE, Miller RD. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology73, 410–414 (1990).
   PubMed Web of Science ®Google Scholar
• van den Broek L, Proost JH, Wierda JM. Early and late reversibility of rocuronium bromide. Eur. J. Anesthesiol.11, 128–132 (1994).
   Google Scholar
• Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate acting neuromuscular blocking drugs. Anesthesia56, 312–318 (2001).
   PubMed Web of Science ®Google Scholar
• Berg H, Roed J, Viby-Mogensen J et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anesthesiol. Scand.41, 1095–1103 (1997).
   PubMed Web of Science ®Google Scholar
• Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology92, 977–984 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Marymont JH et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology109, 389–398 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth. Analg.107, 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm.329, 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Challa R, Ahula A, Ali J et al. Cyclodextrins in drug delivery: an updated review. AAPS Pharma. Sci. Tech.6, 329–357 (2005).
   PubMed Web of Science ®Google Scholar
• Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm.225, 15–30 (2001).
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev.59, 645–666 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang M-Q. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future28, 347–354 (2003).
   Web of Science ®Google Scholar
• Bom A, Bradley M, Cameron K. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl.41, 266–270 (2002).
   PubMed Web of Science ®Google Scholar
• Adam JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J. Med. Chem.45, 1806–1816 (2002).
   PubMed Web of Science ®Google Scholar
• Booij LHDJ. Cyclodextrins and the emergence of sugammadex. Anesthesia64(Suppl. 1), 31–37 (2009).
   PubMed Web of Science ®Google Scholar
• Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969. A novel agent to reverse the action of rocuronium bromide. Anesthesiology103, 695–703 (2005).
   PubMed Web of Science ®Google Scholar
• Sorgenfrei IF, Norrild K, Larsen PB et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose finding and safety study. Anesthesiology104, 667–674 (2007).
   Web of Science ®Google Scholar
• Sparr HJ, Vermeyen KM, Beaufort AM et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology106, 935–943 (2007).
   PubMed Web of Science ®Google Scholar
• de Boer HD, van Egmond J, Marcus M, Schouten P, Smeets J, Driessen JJ. Pharmacokinetics of high doses of the selective relaxant binding agent sugammadex, administered shortly after profound rocuronium-induced neuromuscular block. Eur. J. Anesthesiol.23(Suppl. 37), 143 (2006)
   Web of Science ®Google Scholar
• Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology99, 632–637 (2003).
   PubMed Web of Science ®Google Scholar
• Epemolu O, Mayer I, Hope F, Scullion P, Desmond P. Liquid chromatography/mass spectrometric bioanalysis of a modified γcyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun. Mass Spectrom.16, 1946–1952 (2002).
   PubMed Web of Science ®Google Scholar
• Naguib M. Sugammadex: another milestone in neuromuscular pharmacology. Anesth. Analg.104, 575–581 (2007).
   PubMed Web of Science ®Google Scholar
• Staals LM, Snoek MJ, Driessen JJ, Flockton E, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br. J. Anesth.101, 492–497 (2008).
   PubMed Web of Science ®Google Scholar
• Hartman J, Smeets JMW, deZwart MAH, Peters SMA. In-vitro dialysability of sugammadex (Org 25969), a selective relaxant binding agent for reversal of neuromuscular block induced by rocuronium. Eur. J. Anesthesiol.26(Suppl. 37), 144 (2006).
   Google Scholar
• Mason R, Bom A. Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBAs in anesthetized guinea pigs. Eur. J. Anesthesiol.18, 100 (2001).
   PubMed Web of Science ®Google Scholar
• Bom A, Mason R, McIndewar I. Org 25969 causes rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base status. Anesthesiology96, (2002) (Abstract A-1009).
   Google Scholar
• Bom A, Van Egmond J, Hope F et al. Rapid reversal of rocuronium induced neuromuscular block by Org 25969 is independent of renal perfusion. Anesthesiology99 (2003) (Abstract A-1158).
   Google Scholar
• de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey. Br. J. Anesth.96, 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksson LI. Evidence-based practice and neuromuscular monitoring: it’s time for routine quantitative assessment. Anesthesiology98, 1037–1039 (2003).
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology98, 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anesth. Scand.51, 789–808 (2007).
   PubMed Web of Science ®Google Scholar
• Pühringer F, Blaszyk M, Gammu G, Sparr H, Heeringa M. Sugammadex achieves fast recovery from shallow neuromuscular blockade induced by rocuronium or vecuronium: dose-response studies. Eur. J. Anesthesiol.24(Suppl. 39), 111 (2007).
   Web of Science ®Google Scholar
• Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WGF. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology106, 283–288 (2007).
   PubMed Web of Science ®Google Scholar
• Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 µg/kg). Eur. J. Anesthesiol.24(Suppl. 39), 125–126 (2007).
   Web of Science ®Google Scholar
• Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Brit. J. Anes.96, 36–43 (2006).
   PubMed Web of Science ®Google Scholar
• Groudine SB, Soto R, Lien C, Drover D, Roberts K. Randomised, dose finding, Phase 2 study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth. Analg.104, 555–562 (2007).
   PubMed Web of Science ®Google Scholar
• Duvaldestin P, Kuizenga K, Kjaer CC, Saldieen V, Debaene B. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose response study. Eur. J. Anesthesiol.24(Suppl. 39), 123 (2007).
   Google Scholar
• Pühringer FK, Rex C, Sielenkamber AW et al. Reversal of profound, high dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points. An international multicenter, randomised, dose finding, safety assessor-blinded, Phase 2 trial. Anesthesiology109, 188–197 (2008).
   PubMed Web of Science ®Google Scholar
• de Boer HD, Driessen JJ, Marcus MAE, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex. Anesthesiology107, 239–244 (2007).
   PubMed Web of Science ®Google Scholar
• Lee C, Jahr JS, Candiotti K, Warriner B, Zornow M. Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Anesthesiology107, A988 (2007).
   Google Scholar
• Alvarez-Gomez JA, Wattwil M, Vanacker B, Lora-Tamayo JI, Khunl-Brady KS. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur. J. Anesthesiol.24(Suppl. 39), 124–125 (2007).
   Google Scholar
• Jones RK, Caldwell JE, Brull S, Soto R. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology109, 816–824 (2008).
   PubMed Web of Science ®Google Scholar
• Lemmens HJM, El-Orbany M, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology107, A1578 (2007).
   Google Scholar
• Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth. Analg.104, 582–584 (2007).
   PubMed Web of Science ®Google Scholar
• McDonagh DL, Benedict PE, Kovac AL et al. Safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology107, A1583 (2007).
   Web of Science ®Google Scholar
• Plaud B, Meretoja O, Hofmockel R et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology110, 284–294 (2009).
   PubMed Web of Science ®Google Scholar
• Dahl V, Pendeville PE, Hollman MW et al. Reversal of rocuronium induced blockade by sugammadex in cardiac patients. Anesthesiology107, A1581 (2007).
   Google Scholar
• Amao R, Zornow MH, Cowan MR et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology107, A1582 (2007).
   Google Scholar
• Monk TG, Rietbergen H, Woo T. Obesity has no clinically relevant impact upon recovery time following administration of sugammadex. Anesthesiology109, A682 (2008).
   Google Scholar
• de Kam P-J, van Kuijk J, Smeets J et al. Single IV sugammaedx doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology107, A1580 (2007).
   Google Scholar
• Cammu G, De Kam PJ, Demeyer I et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br. J. Anesth.100, 373–379 (2008).
   PubMed Web of Science ®Google Scholar
• Plaud B, van Heumen E, Zweirs A. Sugammadex is well tolerated for the reversal of rocuronium or vecuronium induced neuromuscular blockade in a pooled analysis of adverse events in 10 placebo controlled trials. Eur. J. Anesthesiol.24(Suppl. 39), 111 (2007).
   Web of Science ®Google Scholar
• Mirakhur RK, McCarthy GJ. Basic pharmacology of reversal agents. Anesthesiol. Clin.11, 237–250 (1993).
   Google Scholar
• Bom A, Hope F. Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium. Eur. J. Anesthesiol.22(Suppl. 34), 120 (2005).
   Google Scholar